Back to 2015 Annual Meeting Display Posters

OBJECTIVE: Rapid deployment valves combine the well known and proofed valve design from conventional trileaflet pericardial tissue valves with transcatheter anchoring techniques using a subannular balloon-expandable stent frame. We report our initial single center experience and short term results after rapid deployment valve AVR.
METHODS: 130 patients received rapid deployment AVR between March 2012 and and December 2014. Either isolated AVR using a minimal access technique or a combined procedure were performed. 69% (n=90) of all procedures were isolated AVR procedures. AVR + CABG was performed in 29 patients (22%), a double valve procedure in 9 patients (7,0%) and a triple valve procedure in 3 patients (2,3%).
RESULTS: The mean age was 77,5 (± 5,3) years. 30 day mortality was 4,6% (n=6). A mean logistic Euroscore of 11,2% (± 2,3) was found. The mean crossclamp time was 44 ± 9 min for all procedures
A peak gradient of 21.1 (± 6,1) mmHg and a mean gradient of 10.4(± 4,7) mmHg were measured postoperatively. The mean effective orifice area was 1,7 cm2 (± 0,3).
CONCLUSIONS: Rapid valve deployment AVR is a safe procedure, which can be routinely performed with reproducible short cross clamp and bypass times. Especially minimal access procedures can easily be promoted, by facilitating and accelerating AVR procedures. Furthermore good hemodynamic characteristics can be seen.